Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide in Novel Combinations for RRMM
NCT05372354Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Molecular Glues
- Countries
- 5
01
Overview
Phase 2, open-label trial of mezigdomide in multiple myeloma (MM) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events at 4 years, Number of participants with Serious AEs at 4 years and 4 more. Started Oct 2022; status: recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05372354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372354.